Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!

Range Low Price High Price Comment
30 days $4.03 $5.78 Monday, 13th May 2024 BCRX stock ended at $5.63. This is 5.83% more than the trading day before Friday, 10th May 2024. During the day the stock fluctuated 6.55% from a day low at $5.34 to a day high of $5.69.
90 days $4.03 $6.04
52 weeks $4.03 $8.96

Historical BioCryst Pharmaceuticals prices

Date Open High Low Close Volume
Aug 12, 2016 $5.20 $5.80 $5.00 $5.04 6 046 700
Aug 11, 2016 $5.03 $5.08 $4.93 $5.03 1 496 100
Aug 10, 2016 $4.98 $5.15 $4.83 $5.00 2 682 500
Aug 09, 2016 $4.20 $5.10 $4.18 $4.95 3 950 400
Aug 08, 2016 $4.21 $4.22 $4.06 $4.19 720 000
Aug 05, 2016 $4.10 $4.21 $4.02 $4.14 1 104 000
Aug 04, 2016 $4.22 $4.22 $3.87 $4.00 1 881 600
Aug 03, 2016 $3.77 $4.25 $3.73 $4.03 2 172 500
Aug 02, 2016 $3.69 $3.83 $3.61 $3.77 757 400
Aug 01, 2016 $3.62 $3.74 $3.56 $3.70 652 600
Jul 29, 2016 $3.47 $3.64 $3.40 $3.62 906 600
Jul 28, 2016 $3.41 $3.49 $3.30 $3.46 1 032 300
Jul 27, 2016 $3.02 $3.43 $3.02 $3.41 1 894 800
Jul 26, 2016 $3.03 $3.10 $2.98 $3.00 356 800
Jul 25, 2016 $3.08 $3.08 $2.99 $3.04 295 400
Jul 22, 2016 $2.99 $3.09 $2.95 $3.08 392 100
Jul 21, 2016 $3.00 $3.09 $2.95 $2.98 434 100
Jul 20, 2016 $2.90 $3.04 $2.87 $2.97 504 800
Jul 19, 2016 $3.01 $3.02 $2.87 $2.88 333 200
Jul 18, 2016 $2.96 $3.03 $2.88 $3.02 301 800
Jul 15, 2016 $2.90 $2.97 $2.86 $2.96 317 000
Jul 14, 2016 $2.96 $2.98 $2.85 $2.87 489 100
Jul 13, 2016 $3.09 $3.09 $2.90 $2.91 571 600
Jul 12, 2016 $3.09 $3.13 $3.03 $3.07 457 600
Jul 11, 2016 $3.11 $3.14 $3.00 $3.07 394 800
Click to get the best stock tips daily for free!

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX9930, an oral factor D inhibitor, which is in Phase II... BCRX Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT